Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: 2023

Transgene Announces Upcoming Investor Meetings

upcoming investor meetings

Published 21 December 2023
Categorized as 2023, categorie-orpheline, dates, dates, Press release

Transgene Strengthens its Leadership Team to Accelerate its Growth Strategy

nomination A Dubarry

Published 5 December 2023
Categorized as 2023, categorie-orpheline, dates, dates, Press release

Transgene reports business update and Q3 2023 financial position

Q3 2023 financial position

Published 7 November 2023
Categorized as 2023, categorie-orpheline, dates, dates, Press release

Transgene and BioInvent – First patient treated in Part B of Phase I trial assessing the novel oncolytic virus BT-001 in combination with KEYTRUDA®(pembrolizumab)

Transgene and BioInvent – first patient treated in Part B of Phase I trial

Published 10 October 2023
Categorized as 2023, BT-001, categorie-orpheline, dates, dates, Press release

Transgene advances its innovative immunotherapy pipeline and extends financial visibility until the end of 2024

2023 half year results and business update

Published 20 September 2023
Categorized as 2023, categorie-orpheline, dates, dates, Press release

Transgene Announces Upcoming Investor Meetings

Transgene Announces Upcoming Investor Meetings

Published 14 September 2023
Categorized as 2023, categorie-orpheline, dates, dates, Press release

Phase Ib/II trial of tipapkinogene sovacivec (TG4001), a therapeutic human papillomavirus 16-vaccine, in combination with avelumab in patients with advanced human papillomavirus 16-positive cancers

C. Le Tourneau, et al.European Journal of Cancer, July 2023 (191)Access the article herePublication

Published 29 August 2023
Categorized as -others, 2023, Publication, TG4001, TG4001

Transgene receives $15.3 Million from the Sale of Securities Held for Sale

Transgene receives $15.3 million from the sale of securities held for sale

Published 17 July 2023
Categorized as 2023, categorie-orpheline, dates, dates, Press release

Transgene and NEC Present New Data on TG4050, an Individualized Cancer Vaccine, Showing it Induces Specific Immune Responses against Head and Neck Carcinoma at ASCO 2023

Transgene and NEC present New Data on TG4050 at ASCO 2023

Published 6 June 2023
Categorized as 2023, categorie-orpheline, dates, dates, Myvac, Press release, TG4050

Transgene presents immunological data demonstrating that TG4001, a novel therapeutic cancer vaccine, can induce T-cell responses against HPV16 antigens in the ongoing Phase II trial at ASCO 2023

Transgene immunological data demonstrating that TG4001 can induce T-cell responses

Published 5 June 2023
Categorized as 2023, categorie-orpheline, dates, dates, Press release, TG4001, TG4001

Posts pagination

Page 1 … Page 4 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu